Standout Papers

Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial 2019 2026 2021 2023 360
  1. Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial (2019)
    Robert D. McBane, Waldemar E. Wysokiński et al. Journal of Thrombosis and Haemostasis

Immediate Impact

3 from Science/Nature 59 standout
Sub-graph 1 of 23

Citing Papers

Multiple myeloma
2024 Standout
A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy
2024 Standout
1 intermediate paper

Works of Daniel M. Anderson being referenced

Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma
2019

Author Peers

Author Last Decade Papers Cites
Daniel M. Anderson 254 194 311 373 316 34 1.2k
A. Weltermann 113 103 483 525 327 34 1.0k
J.F. Martin 30 31 136 516 551 32 1.3k
Andrew Eisenberger 282 78 92 139 295 50 1.1k
Leila A. Kutteh 622 59 175 113 134 23 977
Susan S. Smyth 70 64 361 154 234 47 1.1k
M.‐T. Barrellier 114 33 79 279 144 40 1.2k
Diana Farris 118 90 717 677 352 30 1.4k
Yona Nadir 119 93 396 225 118 65 1.1k
Carolyn Whitsett 47 335 499 187 146 45 1.3k
Thomas W. Wakefield 21 33 227 743 342 41 1.2k

All Works

Loading papers...

Rankless by CCL
2026